Results 11 to 20 of about 13,748 (197)
Cancer Research, Statistics, and Treatment, 2021 Lung cancer diagnostics and therapeutics have witnessed a paradigm shift in the last decade because of the discovery of targetable biomarkers and rapid approvals of the corresponding targeted therapies.
Ullas Batra +2 more
doaj +2 more sources
Pediatric NTRK fusion sarcomas [PDF]
Diagnostic Pathology, 2020 Abstract Background While ETV6-NTRK3 fusion is common in infantile fibrosarcoma, NTRK1 fusion in pediatric sarcoma is extremely rare and consequently not well known. Herein, we evaluated NTRK1 fusion pediatric sarcomas to determine their clinicopathological nature and differential diagnosis from classic ETV6-NTRK3 fusion infantile fibrosarcoma.
Jeongwan Kang +9 more
openaire +4 more sources
NTRK fusion in Japanese colorectal adenocarcinomas [PDF]
Scientific Reports, 2021 AbstractNTRK fusion-positive tumors are known to be highly sensitive to TRK inhibitors, such as larotrectinib and entrectinib. Therefore, identification of patients who can potentially benefit from these inhibitors is important; however, the frequency of NTRK fusions in Japanese patients with colorectal cancer (CRC) is unknown.
Yuya Yamashiro +6 more
openaire +3 more sources
NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
Frontiers in Oncology, 2022 Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer (NSCLC) with a frequency of approximately less than 1%.
Fangfang Liu +5 more
doaj +1 more source
NTRK insights: best practices for pathologists [PDF]
Modern Pathology, 2022 Since the discovery of an oncogenic tropomyosin-receptor kinase (TRK) fusion protein in the early 1980s, our understanding of neurotrophic tropomyosin-receptor kinase (NTRK) fusions, their unique patterns of frequency in different tumor types, and methods to detect them have grown in scope and depth. Identification of these molecular alterations in the
openaire +2 more sources
gene amplification in patients with metastatic cancer [PDF]
Precision and Future Medicine, 2017 Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of cancers, and tyrosine kinase inhibitors targeting the tropomyosin receptor kinase (TRK) receptor are currently in clinical trials. However, no reports are
Su Jin Lee +13 more
doaj +1 more source
NTRK Gene Fusion Detection in Atypical Spitz Tumors [PDF]
International Journal of Molecular Sciences, 2021 Atypical Spitz tumors (AST) deviate from stereotypical Spitz nevi for one or more atypical features and are now regarded as an intermediate category of melanocytic tumors with uncertain malignant potential. Activating NTRK1/NTRK3 fusions elicit oncogenic events in Spitz lesions and are targetable with kinase inhibitors.
Rocco Cappellesso +21 more
openaire +3 more sources
Unusual presentation of lipofibromatosis-like neural tumor in an adult: A case report
Saudi Journal of Medicine and Medical Sciences, 2021 Lipofibromatosis-like neural tumor (LPF-NT) is a rare variant of lipofibromatosis. Standard lipofibromatosis tumors show a predilection for the distal extremities of male children or young adults and are typically painless, slow-growing, subcutaneous or ...
Muhammad Samsoor Zarak +9 more
doaj +1 more source
JTO Clinical and Research Reports, 2023 The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC.
Mary C. Boulanger, MD +4 more
doaj +1 more source
NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
Diagnostics, 2021 Tropomyosin receptor kinase (TK) is encoded by the neurotrophic tyrosine receptor kinase genes (NTRK) 1, 2, and 3, whose activation plays an important role in cell cycle proliferation and survival.
Vasiliki Siozopoulou +4 more
doaj +1 more source